Cellectar Biosciences, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

ACCRUED EXPENSES

ACCRUED EXPENSES

12 Months Ended

Dec. 31, 2019

ACCRUED EXPENSES

ACCRUED EXPENSES

6. ACCRUED EXPENSES

Accounts payable and accrued liabilities approximately consist of the following:


		2019			2018

Incentive compensation		$	395,000		$	408,000
Accounts payable			1,278,000			612,000
Clinical study costs			720,000			332,000
Professional fees			157,000			64,000
Insurance			111,000			69,000
Other			3,000			59,000
		$	2,664,000		$	1,544,000